A Avan
Overview
Explore the profile of A Avan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
298
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nedaeinia R, Manian M, Jazayeri M, Ranjbar M, Salehi R, Sharifi M, et al.
Cancer Gene Ther
. 2016 Dec;
24(2):48-56.
PMID: 27982021
The most important biological function of exosomes is their possible use as biomarkers in clinical diagnosis. Compared with biomarkers identified in conventional specimens such as serum or urine, exosomal biomarkers...
2.
Hassanian S, Avan A, Ardeshirylajimi A
J Thromb Haemost
. 2016 Dec;
15(2):213-218.
PMID: 27925683
Inorganic polyphosphate (PolyP) is a molecule with prothrombotic and proinflammatory properties in blood. PolyP activates the NF-κB signaling pathway, increases the expression of cell surface adhesion molecules and disrupts the...
3.
Jazayeri M, Amani H, Pourfatollah A, Avan A, Ferns G, Pazoki-Toroudi H
Cancer Gene Ther
. 2016 Oct;
23(10):365-369.
PMID: 27740614
Prostate-specific antigen (PSA) is used to screen for prostate disease, although it has several limitations in its application as an organ-specific or cancer-specific marker. Furthermore, a highly specific/sensitive and/or label-free...
4.
Mirhafez S, Ebrahimi M, Saberi Karimian M, Avan A, Tayefi M, Heidari-Bakavoli A, et al.
Eur J Clin Nutr
. 2016 Jul;
70(11):1298-1304.
PMID: 27460263
Background/objectives: Metabolic syndrome (MetS) is characterized by abdominal obesity, dyslipidemia, hypertension and glucose intolerance, and is associated with an increased risk of developing cardiovascular disease (CVD), diabetes mellitus and related...
5.
Nedaeinia R, Sharifi M, Avan A, Kazemi M, Rafiee L, Ghayour-Mobarhan M, et al.
Cancer Gene Ther
. 2016 Jul;
23(8):246-53.
PMID: 27364574
Colorectal cancer (CRC) is the third leading cause of cancer-related death and has an extremely poor prognosis. Dysregulation of microRNAs (miRNAs) has been shown to be involved in the pathogenesis...
6.
Changizi-Ashtiyani S, Alizadeh M, Najafi H, Babaei S, Khazaei M, Jafari M, et al.
Cancer Gene Ther
. 2016 Jun;
23(7):235-40.
PMID: 27255563
Cisplatin is frequently being used for the treatment of different tumors, although the application of this agent is associated with nephrotoxicity. Here, we explored the antioxidant and anti-inflammatory activities of...
7.
Maftouh M, Avan A, Sciarrillo R, Granchi C, Leon L, Rani R, et al.
Br J Cancer
. 2013 Nov;
110(1):172-82.
PMID: 24178759
Background: Hypoxia is a driving force in pancreatic-ductal-adenocarcinoma (PDAC) growth, metastasis and chemoresistance. The muscle-isoform of lactate dehydrogenase (LDH-A) constitutes a major checkpoint for the switch to anaerobic glycolysis, ensuring...
8.
Avan A, Maftouh M, Funel N, Ghayour-Mobarhan M, Boggi U, Peters G, et al.
Curr Med Chem
. 2013 Sep;
21(8):975-89.
PMID: 23992325
The receptor tyrosine kinase mesenchymal-epithelial transition factor (c-Met) plays a pivotal role in regulation of cell proliferation and migration. Abnormal expression of c-Met has been associated with poor prognosis in...